News
-
-
PRESS RELEASE
VIEL & Cie :1er semestre 2025 : Chiffre d’affaires consolidé en hausse de 9,4 % à 653,5 millions d’euros à cours de change variables (+ 9,9 % à cours de change constants)
VIEL & Cie affiche une croissance de 9,4% de son chiffre d'affaires consolidé au 1er semestre 2025, atteignant 653,5 millions d'euros. Le marché financier marque une forte volatilité -
-
PRESS RELEASE
VALNEVA : Rapport Semestriel 2025
-
-
PRESS RELEASE
Sonova expands Infinio range and enters new market segment with Phonak’s smallest and first rechargeable in-the-ear hearing aid
Sonova expands Infinio range with Phonak's smallest rechargeable in-the-ear hearing aid, Phonak Virto R Infinio. The launch marks an important step in entering the market segment -
-
-
PRESS RELEASE
Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia patients, targeting TRS population -
